Journal
MOLECULAR THERAPY-NUCLEIC ACIDS
Volume 26, Issue -, Pages 174-191Publisher
CELL PRESS
DOI: 10.1016/j.omtn.2021.07.017
Keywords
-
Categories
Funding
- Instituto de Salud Carlos III
- FEDER
- la Caixa Banking Foundation [PI17/00352, HR17-00268]
- Precipita Project titled Desarrollo de una terapia innovadora contra la distrofia miotonica
- Fondo Social Europeo for science and investigation [APOSTD/2019/142, APOSTD/2017/088]
- Generalidad Valenciana [Grisolip2018/098]
- Generalitat Valenciana
- ERDF funds (OP ERDF of Comunitat Valenciana 2014-2020)
Ask authors/readers for more resources
This study presents preclinical characterization of an antagomiR-218 molecule in a mouse model and patient-derived myotubes, demonstrating its effectiveness in rescuing molecular and functional phenotypes in a dose- and time-dependent manner. The antagomiR improved subcellular distribution of Mbnl1 in muscle tissue and rescued defective fusion and differentiation in patient-derived cells. Importantly, the upregulation of miR-218 in DM1 muscle biopsies indicates its potential as a therapeutic target.
Myotonic dystrophy type 1 (DM1) is a rare neuromuscular disease caused by expansion of unstable CTG repeats in a non-coding region of the DMPK gene. CUG expansions in mutant DMPK transcripts sequester MBNL1 proteins in ribonuclear foci. Depletion of this protein is a primary contributor to disease symptoms such as muscle weakness and atrophy and myotonia, yet upregulation of endogenous MBNL1 levels may compensate for this sequestration. Having previously demonstrated that antisense oligonucleotides against miR-218 boost MBNL1 expression and rescue phenotypes in disease models, here we provide preclinical characterization of an antagomiR-218 molecule using the HSA(LR) mouse model and patient-derived myotubes. In HSA(LR), antagomiR-218 reached 40-60 pM 2 weeks after injection, rescued molecular and functional phenotypes in a dose- and time-dependent manner, and showed a good toxicity profile after a single subcutaneous administration. In muscle tissue, antagomiR rescued the normal subcellular distribution of Mbnl1 and did not alter the proportion of myonuclei containing CUG foci. In patient-derived cells, antagomiR-218 improved defective fusion and differentiation and rescued up to 34% of the gene expression alterations found in the transcriptome of patient cells. Importantly, miR-218 was found to be upregulated in DM1 muscle biopsies, pinpointing this microRNA (miRNA) as a relevant therapeutic target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available